PRS-332 / Palvella Therapeutics - LARVOL DELTA

Pieris loses Servier as partner for cancer immunotherapies (pharmaphorum) - "In a Securities & Exchange Commission (SEC) filing, Pieris said that Servier will exit the agreement between the two companies – first agreed in 2017 and focusing on the development of several Anticalin-based therapeutics for cancer – before the end of the year...The prompt for Servier's exit was a decision to stop dosing S095012 (formerly PRS-344), a 4-1BB/PD-L1 bispecific protein, in a phase 1 trial. Pieris said it intends to review the safety data from the S095012 study to understand the implications of the data, but does not intend to pursue any further development of the drug....Servier paid Pieris $31 million to start up the alliance, which spanned five bispecific drugs and could have been worth up to $1.8 billion. The lead drug at the time of signing was PRS-332, a CD223/PD-L1 bispecific protein that also seems to have fallen by the wayside."

Discontinued • Licensing / partnership • Trial termination • Oncology • Solid Tumor

Pieris Pharmaceuticals and Seattle Genetics announce multi-program immuno-oncology collaboration (GlobeNewswire) - "Pieris Pharmaceuticals, Inc...and Seattle Genetics, Inc....announced they have entered into a collaboration and license agreement with the goal of developing multiple targeted bispecific immuno-oncology treatments for solid tumors and blood cancers."

Licensing / partnership